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A
dulthemoglobin(HbA)existsasatetramerofnoncovalently
boundglobinchains,consistingoftwoRandtwoβsubunits.
Fetal hemoglobin (HbF), with its increased oxygen aﬃnity, is
composed of two R and two γ subunits (R2γ2). The γ subunits
are homologous to the β chain, diﬀering by 39 amino acids, and
fetal hemoglobin is usually present in the blood until six months
afterbirth.Theγsubunitscompriseofone
Aγandone
Gγ,which
corresponds to the amino acid at position 136 in the globin
chains (
Aγ an alanine and
Gγ a glycine).
1 Abnormalities of
hemoglobin, hemoglobinopathies, are the most common type
of inherited disease. According to the hemoglobin variant
database HbVar (http://globin.cse.psu.edu), there are over
1000 hemoglobin (Hb) variations.
2 These variants are usually
the result of point mutations in a globin gene producing a single
amino acid substitution in a globin chain, most commonly the
β chain.
The vast majority of Hb variants have little clinical signiﬁ-
cance; however, the HbS mutation, in which a glutamic acid at
position 6 in the β chain is substituted for valine (Δm = 29.9745
Da),isresponsibleforsicklecelldisease.Sicklecelldiseaseaﬀects
the oxygen-carrying capacity of red blood cells. The sickle trait is
caused by one abnormal allele of the hemoglobin β gene
(heterozygous) and does not display the severe symptoms of
homozygotes. Patients with sickle cell disease experience re-
duced life spans,
3 and 15% of young children with sickle cell
disease die due to acute infections and other sickle-related
complications. The rapid detection of sickle cell disease drama-
tically reduces mortality in the ﬁrst 5 years of life.
4
Other common hemoglobinopathies include hemoglobin C
(HbC)inwhichposition6oftheβchainissubstituted(glutamic
acid to lysine) resulting in a mass diﬀerence of less than -1D a
(Δm = 0.9476 Da). The disease state requires both abnormal
genes, HbCC (homozygote), whereas trait, HbAC (hetero-
zygote), is asymptomatic. Symptoms of the disease state include
mild/moderate anemia and hemolysis.
5 The coinheritance of βS
and βC (HbSC) leads to a sickling disorder similar to sickle cell
disease but generally less severe.
6 The hemoglobin D variant is
caused by a mutation on the β chain at position 121 (glutamic
acidforaglutamine),alsoresultinginamassshiftoflessthan-1
Da (Δm = 0.9840 Da). The hemoglobin D (HbAD) trait
(heterozygote)againcausesnoclinicalmanifestationsbutifcoin-
heritedwithsickle(HbSD)causesconsiderable sickle-like health
problems. In its homozygous state, HbD causes hemoglobin D
disease which manifests as mild to moderate anemia.
7,8 Hb
variants with signiﬁcant clinical outcomes, such as homozygous
sickle cell disease, have a prevalence rate of 1 in 2000 births.
9,10
Overa2yearscreeningperiod,17000carriers(heterozygousfor
Hb variants) were identiﬁed from almost 1.2 million infants.
10
Earlyscreeningforhemoglobinopathiesallowsforappropriate
genetic counselling and an improvement in the outcome of
patients with sickle cell disease. Newborn blood screening has
been adopted in the majority of countries around the world. The
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ABSTRACT: Hemoglobinopathies are the most common inherited disorders. New-
born blood screening for clinically signiﬁcant hemoglobin variants, including sickle
(HbS), HbC, and HbD, has been adopted in many countries as it is widely acknowl-
edged that early detection improves the outcome. We present a method for
determination of Hb variants by direct surface sampling of dried blood spots by use
of an Advion Triversa Nanomate automated electrospray system coupled to a high-
resolution mass spectrometer. The method involves no sample preparation. It is
possible to unambiguously identify homozygous and heterozygous HbS, HbC, and HbD variants in <10 min without the need for
additionalconﬁrmation.Themethodallowsforrepeatedanalysisofasinglebloodspotoveraprolongedtimeperiodandistolerant
of blood spot storage conditions.2266 dx.doi.org/10.1021/ac1030804 |Anal. Chem. 2011, 83, 2265–2270
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U.K. screening program screens over 700000 newborns a year
for sickle cell disease,
10 as well as congenital hypothyroidism
(CHT), phenylketonuria (PKU), cystic ﬁbrosis (CF), and medi-
um chain acyl-CoA dehydrogenase deﬁciency (MCADD).
11
Blood samples are taken 5-8 days after birth via a heel prick
and collected on ﬁlter paper cards. The majority of laboratories
participating in the screening process employ cation exchange
high-performance liquid chromatography (ceHPLC) followed
by isoelectric focusing (IEF) for result conﬁrmation.
10,12 Sub-
sequent amino acid sequencing of unusual abnormalities means
the entire process can take weeks or even months for some
variants.
13 Preparation of samples for both ceHPLC and IEF
involves punching out 3 mm blood spots discs from the blood
spotcardandelutionofthesamplefor20-30min.ForceHPLC
analysis,theruntimepersampleis3minwhereasforIEFitis∼2
h.
14 Hb has a characteristic retention time in ceHPLC, and
variants are presumptively determined from deviations in that
retention time. Problematically, some hemoglobin variants coe-
lute, e.g., HbA2, Hb Lepore, and HbE, making results incon-
clusive and diﬃcult to interpret.
12,15 ceHPLC is advantageous in
that it can be used for quantiﬁcation.
16 Hb variants are identiﬁed
by IEF by comparing pI values with those for control Hb. Again,
identiﬁcation is presumptive rather than absolute.
A procedure for identifying Hb variants by electrospray
ionization (ESI) mass spectrometry of diluted whole blood has
been described.
17-19 That method involves molecular weight
determinationofintactglobinchainstoconﬁrmthepresenceofa
variant followed by tryptic digestion of the blood sample and
tandem mass spectrometry to identify the site of mutation.
Dalton and co-workers have shown that multiple reaction
monitoring (MRM) ESI tandem mass spectrometry (MS/MS)
of tryptic digests of whole blood can be applied to the identiﬁca-
tion of Hb variants.
20 In 2004, Wild et al.
21 described a method
for the analysis of Hb variants from dried blood spots in which
the blood spot is punched out and resolubilized prior to ESI MS
of intact globin chains. Dalton and co-workers have since shown
that the MRM method can be applied to samples that have been
eluted from blood spots and digested with trypsin.
22
The methods described above are characterized by lengthy
sample preparation and/or ambiguous variant determination.
The ideal method would encompass direct analysis of the dried
blood spot (i.e., no requirement for sample preparation) and
absolute identiﬁcation of the variant from the intact globin
chains. Direct analysis of dried blood spots by desorption
electrospray ionization (DESI) has been demonstrated for the
quantitation of xenobiotics.
23 Earlier this year, Van Berkel and
co-workers showed that liquid microjunction surface sampling
24
(orliquidextractionsurfaceanalysis)couldalsobeappliedtothe
quantitation of xenobiotics.
25 Liquid microjunction surface sam-
pling was achieved by use of an Advion TriVersa Nanomate via
the advanced user interface (AUI) platform of the NanoMate
ChipSoftManager software.
Herewehaveappliedliquidmicrojunctionsurfacesamplingof
dried blood spots coupled to a high-resolution orbitrap mass
spectrometer for the analysis of Hb variants. The method invol-
ves no sample preparation other than mounting the dried blood
spot card on a microtiter plate. Hb was directly extracted and
electrosprayed into the mass spectrometer. The orbitrap mass
spectrometer
26 is a high-resolution instrument, and it was possi-
ble in selected ion monitoring mode to unambiguously identify
both homozygous and heterozygous sickle cell disease (Δm
29.9745 Da). The entire analysis time was 5 min. The variants
HbC (both homo- and heterozygous) and HbD (heterozy-
gous) (Δm < 1 Da) were unambiguously identiﬁed by colli-
sion-induced dissociation tandem mass spectrometry (CID
MS/MS). The analysis time was 5-7 min. In addition to
meeting the criteria above, namely, fast, direct, and unambig-
uousdeterminationofHbvariantswithnosamplepreparation,
the method allows for repeated analysis of the dried blood
spots with no loss ofmassspectralresponseoveraprolongedtime
period (months).
’EXPERIMENTAL SECTION
Materials. Driedbloodspotsfromnormaladults(HbA)were
collected on standard NHS blood spot cards. Anonymized dried
blood spots from normal neonates (FA), heterozygous (FAS)
andhomozygous(FS)sickletraitneonates,heterozygous(FAC)
and homozygous (FC) variant C, and heterozygous (FAD) vari-
ant D, acquired from newborn patients between 5 and 8 days,
weresuppliedbyBirminghamChildren’sHospital,inaccordance
with the Code of Practice for the Retention and Storage of
ResidualSpots.
27Sampleswerestoredatroomtemperatureprior
toanalysis.Theelectrospraysolutionconsistedofmethanol(J.T.
Baker, Deventer, The Netherlands) and water (J.T. Baker)
(48.5:48.5), with 3% formic acid (Sigma-Aldrich Company
Ltd., Dorset, U.K.).
Surface Sampling. The individual dried blood spot samples
were attached to a 96-well microtiter plate (ABgene PCR plate
Thermo Fisher Scientific, Leicestershire, U.K.) using clear tape
and placed in the TriVersa Nanomate chip-based electrospray
device (Advion, Ithaca, NY) (Figure 1a) coupled to the Thermo
Fisher Scientific Orbitrap Velos (Thermo Fisher Scientific, Bre-
men, Germany).
Sample analysis was performed using the advanced user
interface (AUI) feature of the TriVersa NanoMate ChipSoft
Figure 1. Liquid microjunction surface sampling of dried blood spots: (a) blood spot is mounted on TriVersa Nanomate autosampler, (b) sample is
wetted with a solution comprising water/methanol/formic acid and the liquid microjunction forms, (c) solution containing the sample is reaspirated.2267 dx.doi.org/10.1021/ac1030804 |Anal. Chem. 2011, 83, 2265–2270
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Manager software, which controls the TriVersa Nanomate. This
platform was used to construct a surface-sampling routine based
on robotic arm movements (X, Y, Z) of the Nanomate probe.
The routine began with (1) the probe collecting a conductive tip
(used for sample wetting/recovery and delivery) from the
Advion tip rack and moving to a position above a well (located
by predetermined grid coordinates) containing a wetting/as-
pirating solution comprising water/methanol/formic acid
(48.5:48.5: 3, v/v). (2) The tip descended to a depth of 2 mm
from the bottom of the well and aspirated 7 μL of the electro-
spraysolution.(3)Theroboticarmrelocatedtoapredetermined
discrete location above the dried blood spot sample (usually the
center)thendescendedtojustabovethesample.(4)Thetipwas
lowered, and a proportion of the volume of solution (6 μL) was
dispensedformingaliquid microjunction (LMJ)betweenthetip
and blood spot. For this study, the ideal depth for tip-to-sample
LMJ formation equated to 15.6 mm from the base of the well
(Figure 1b). (5) After a user-deﬁned delay of 5 s, during which
the LMJ was maintained allowing suﬃcient time for some of the
sample to be dissolved and mixed, 5 μL of the solution was
reaspirated into the tip (Figure 1c). (The disparity between
volume dispensed and reaspirated allows for evaporation).
Empirical observations suggest that delays <5 s result in poor
signal-to-noise, and delays >8 s result in collapse of the LMJ. (6)
The tip engaged with the back of the ESI chip, and nanospray
ionization was initiated. The Triversa Nanomate was coupled
with a Thermo Fisher Scientiﬁc Orbitrap Velos mass spectro-
meter.
Mass Spectrometry. The sample was introduced at flow rate
of ∼80 nL/min, with a gas pressure of between 0.4 and 0.5 psi, a
tip voltage of 1.75 kV, and a capillary temperature of 250  C. MS
data was collected in full scan mode (m/z 700-1400) with a
resolution of 100000 at m/z 400 and in selected ion monitoring
(SIM)mode(m/z1055-1090)ataresolutionof100000atm/z
400. Each scan comprises 15 coadded microscans. The mass
spectra shown are comprised of approximately 20 scans. Auto-
maticgain control (AGC) wasusedtoaccumulate sufficient ions
for analysis. The AGC target was 1   10
6 with a maximum fill
time of 1 s in full scan mode and 1.5 s SIM mode. CID was
performed in the ion trap, and the fragment ions detected in the
orbitrapwitharesolutionof100000atm/z400.TheAGCtarget
was1 10
6withamaximumfilltimeof2sandanisolationwidth
of 10 Th. CID experiments were performed with helium gas at a
normalized collision energy of 35%. Each CID scan comprises
∼30 coadded microscans. The MS/MS spectra shown (m/z
300-2000) are comprised of 10 coadded scans. Data were
analyzedusingXcalibur2.10software(ThermoFisherScientific)
where the Xtract program was used to calculate monoisotopic
masses (44% fit factor, 25% remainder).
Figure2. (a)Fullscanand(inset)selectedionmonitoring(SIM)modemassspectraofadulthemoglobinHbA.Peakslabeledinredcorrespondtothe
R chains, blue to the β chains; SIM mode mass spectra of (b) normal neonate hemoglobin; (c) neonate heterozygous sickle hemoglobin FAS; (d)
neonate homozygous sickle hemoglobin FS. Peaks labeled
Gγ and
Aγ denote γ chains containing glycine or alanine at position 136, respectively.2268 dx.doi.org/10.1021/ac1030804 |Anal. Chem. 2011, 83, 2265–2270
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’RESULTS
Figure 2a shows the full scan mass spectrum acquired follow-
ing liquid microjunction surface sampling of a dried blood spot
from a normal adult. Each sample was analyzed between 3 and 6
times over a period spanning 5 months. The mass spectrum
shows peaks corresponding to R and β chains in various charge
statesandcomprises10coaddedscansacquiredover3min.Note
that the peaks corresponding to the β chain are less intense than
those for the R chain. The β chain contains fewer basic amino
acid residues than the R chain and consequently ionizes less
readily.
Once injected into the mass spectrometer, it is possible to
continuously electrospray the sample for a lengthy period (60
min or more) allowing suﬃcient time to perform additional ana-
lyses (selected ion monitoring (SIM) mode, collision-induced
dissociation (CID)) as discussed below. The inset of Figure 2a
shows a mass spectrum acquired in SIM mode over the m/z
range 880-900. Peaks corresponding to the 17þ charge state of
the R chain (MWmeas 15117.9479, MWcalc 15117.8924, Δ 3.7
ppm) and the 18þ charge state of the β chain (MWmeas
15858.4251, MWcalc 15858.2570, Δ 10.6 ppm) are observed.
Peaks corresponding to ions of three major species are
observed in the full scan mass spectrum obtained following
liquid microjunction surface sampling of a dried bloodspot from
anormalneonate:Rchain,fetalγchain,andverylowabundance
β chain. Given that the most severe Hb variants occur in the β
chain, the low abundance of these ions could be a problem.
However,withacquisitionofdataintheSIMmode,thesignal-to-
noise is improved signiﬁcantly, see Figure 2b. The measured
masses of the R, β, and γ chains were MWmeas15117.8208 Da,
MWmeas 15858.2680 Da, and MWmeas15986.2933 Da (MWcalc
15986.2626 Da, Δ 1.9 ppm), respectively.
HbSVariant. Withconfirmationthatthemethodwassuitable
for the analysis of neonatal samples, it was applied to samples
homozygous and heterozygous for HbS. It was not possible to
determine the presence of HbS from the full scan mass spectra;
however, with the data acquired in SIM mode, the variant could
be identified unambiguously (MWmeas 15828.2408 Da; MWcalc
15828.2828 Da, Δ 2.7 ppm) (Figure 2c,d). The sickle trait
sample (heterozygous) can clearly be identified as such by the
presence of both the β-chain and the sickle chain, whereas the
SIMmodemassspectrumofhomozygoussampleshowsnopeak
corresponding to the β-chain. The [M þ 15H]
15þ ions of the β
and sickle chains from the heterozygous sample were each
selected for CID and the fragments detected in the orbitrap.
The MS/MS spectra are shown in Figure SI-1 in the Supporting
Information, with the sequence coverage obtained shown in the
inset.CIDoftheβionsgaveasequencecoverageof39%.Forthe
sickle chain ions, sequence coverage was 32%. The sickle variant
istheresultofsubstitutionatposition6ontheβchain.Following
CID of the β chain ions, the singly charged b6 fragment was
observed at m/zmeas 677.3628 (m/zcalc 677.3617). No peak was
observedatthatm/zfollowingCIDofthesickleions;however,a
peak was observed at m/z 647.3854, corresponding to a mass
shift of 29.9745 Da (Glu f Val) (m/zcalc 647.3875). For both β
andsicklesamples,peakscorrespondingtosinglychargedb4ions
were observed at m/zmeas 451.2669 and 451.2661, respectively
(m/zcalc 451.2663). Expanded m/z regions showing representa-
tive fragments b22
3þ and b47
4þ are shown in Figure 3a,b.
HbC Variant. The HbC variant is the result of a Glu f Lys
substitution at position 6 on the β chain with an associated mass
shift of 0.9476 Da. Figure 4a shows the mass spectra obtained in
SIM mode from normal, heterozygous HbC and homozygous
HbC samples. Comparison of these SIM mode spectra does not
revealthepresenceoftheHbCvariantineithertheheterozygous
or homozygous form. The spectra were deconvoluted by use of
the Xtract software (Thermo Fisher Scientific) to determine the
monoisotopic masses of the ions. The measured MW of the β
chain from the normal neonate sample was 15858.2680 Da. For
the homozygous variant C sample, the measured MW was
15857.4033 Da (MWcalc 15857.3094, Δ 5.9 ppm), suggesting
thepresenceofavariantwithamassshiftof-1Da.However,the
molecular weight obtained following deconvolution of the
heterozygous sample was 15857.2442 Da suggesting the pre-
sence of the variant but failing to reveal the presence of the β
chain. To confirm the presence or otherwise of the HbC variant,
Figure 3. Expanded regions of CID MS/MS spectra showing peaks
correspondingto(a)b22
3þfragmentionsand(b)b47
4þfragmentionsof
the β chain and sickle variant. Measured monoisotopic m/z values
are given.
Figure 4. (a) SIM mode mass spectra from normal FA (top), hetero-
zygous HbC (middle), and homozygous HbC (bottom). (R, β, γ (
Gγ,
and
Aγ) chains are indicated; (b) Expanded m/z regions showing the
b22
3þ fragments observed following CID of the β chain ions (m/zcalc
802.0884) (black) and HbC variant ions (m/zcalc 801.7725) (red).2269 dx.doi.org/10.1021/ac1030804 |Anal. Chem. 2011, 83, 2265–2270
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in each sample the ions centered at m/z 1058 were selected and
subjected to CID. Figure 4b (top) shows an expanded m/z
region containing the b22
3þ fragment ion of the β chain (mono-
isotopic m/zmeas 802.0898, m/zcalc 802.0884). That fragment
was also observed for the heterozygous sample (Figure 4 (mid-
dle)) and is accompanied by the b22
3þ fragment of the HbC
variant (monoisotopic m/zmeas 801.7727, m/zcalc 801.7725). In
the MS/MS spectrum obtained from the homozygous sample
(Figure 4b (bottom)), only the b22
3þ fragment of the HbC
variant is observed. Further examples (b14
2þ and b47
4þ) are
given in SI-2 in the Supporting Information.
HbD Variant. The HbD (Punjab/Los Angeles) variant is the
result of a Glu f Gln substitution at position 121 of the β chain
resultinginamassshiftof-0.9840Da.Althoughthemassshiftis
greater than for HbC, the HbD variant is more challenging to
identify because of the problem of overlapping isotope peaks.
The difference in mass between the
13C isotope of HbD and the
12C isotope of the β chain is 0.0194 Da. Figure SI-3 in the
Supporting Information shows the SIM mode mass spectra
obtained from normal and heterozygous HbD. As for HbC, we
areunabletoconfirmthepresenceofthevariantdirectlyfromthe
SIMspectrum.The[Mþ15H]
15þionsofHbD/βwereisolated
and subjected to CID. The resulting mass spectrum was com-
paredwiththatobtainedfollowingCIDof[Mþ15H]
15þionsof
the β chain. Expanded m/z regions showing the y32
4þ fragments
are shown in Figure 5. Note that for the peaks at m/z 872.7
(
13Cβ/
13C2HbD) and m/z 872.95 (
13C2β/
13C3HbD) in the
lower spectrum (heterozygous D), the peak shapes suggest the
presenceofthetwospecies.FurtherexamplesaregiveninFigure
SI-4 in the Supporting Information.
’DISCUSSION
The results demonstrate the suitability of direct liquid micro-
junction sampling of newborn dried blood spots, by use of a
Triversa Nanomate chip-based electrospray device coupled with
a high-resolution orbitrap mass spectrometer, for the unambig-
uous determination of Hb variants. No preparation of clinical
samples is required, thus sample handling and any subsequent
risks are minimized. The inherent low abundance of β chain in
newborn blood samples can be addressed by acquiring mass
spectraldatain SIMmode.DetectionoftheHbSvariantin the
SIM mode is straightforward. The mass shift of ∼30 Da
equates to an m/z shift of ∼2f o ra1 5 þ ion which is easily
detectable in an orbitrap mass spectrometer. The presence/
absence of peaks at m/z ∼1056.7 (HbS) and ∼1058.7 (β)
a l l o w so n et od e t e r m i n et h ep r e s e n c ea n dt h et y p e( d i s e a s eo r
trait)ofsicklecelldiseasewithoutMS/MS.Theentireanalysis
is complete in less than 5 min. Variants HbC and HbD can
be identiﬁed following CID MS/MS analysis of the intact
chains which takes a further 5-8 min. As HbC and HbD
cannot be identiﬁed directly from the SIM mode scan, if this
methodweretobeincorporatedwithinascreeningprogram,it
would be necessary to perform CID analyses on all samples if
the aim of the program is to detect these variants in addition
to HbS.
Atpresent,themethodisautomatedintermsofanalysisofthe
sample and semiautomated in terms of sample loading. Several
dried blood spots are ﬁxed to a single multiwell plate and their
coordinates determined. A program sequence is set up such that
eachdriedbloodspotmaybesampled(SIMmodeandMS/MS)
during an unattended run. Successful incorporation in a screen-
ing program would require automated loading of the samples
onto the plate.
Although, clearly the method is destructive, each analysis
samples such a tiny fraction of the blood spot that numerous
repeats can be performed. Approximately 8.5% of the total
surface area is wetted during each surface sampling routine,
and empirical observation reveals that each discrete location can
be reanalyzed2-3 times. That suggests thateachbloodspot can
be analyzed up to 35 times. The blood spots used in this study
were stored at room temperature and subjected to multiple
repeat analyses over a time period of 5 months without dis-
cerniblelossofsignal.Themethodisthereforetolerantofstorage
conditions. The possibility for repeat sampling also indicates a
potential drawback of the method: so far, it is not possible to
quantifytherelativeHbcomponentsaswouldberequiredforthe
diagnosis of some thalassemias.
15
The method is potentially applicable to other common Hb
variants, including HbO-Arab, and tounknown variants. Evalua-
tion of the method for those purposes is ongoing.
In this study, we have demonstrated an eﬀective method for
direct surface sampling of dried blood spots for the clinical
analysis of intact proteins. The method allows rapid, unambig-
uousdeterminationofHbvariantsHbS,HbC,andHbD,withno
sample preparation and minimal sample handling. The method
shows greatpromise asa toolfor the screening for Hbvariants in
a clinical setting.
’ASSOCIATED CONTENT
b S Supporting Information. (Figure SI-1) CID MS/MS
spectra of [M þ 15H]
15þ ions of the (a) β and (b) sickle chains
fromaheterozygoussample(sequencecoverageshownininset);
(Figure SI-2) expanded m/z regions of the CID MS/MS spectra
obtained from normal, heterozygous HbC and homozygous
HbC showing the (a) b14
2þ and (b) b47
4þ fragment ions;
(Figure SI-3) SIM mass spectra obtained from normal and
heterozygousHbDsamples;(FigureSI-4)expandedm/zregions
of the CID MS/MS spectra obtained from normal, and hetero-
zygous HbD showing the (a) y47
5þ and (b) y36
4þ fragment ions.
Thismaterial isavailablefree ofchargevia theInternetathttp://
pubs.acs.org.
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